INHBE and colorectal carcinoma: Given the lack of changes in protein expression observed in the stage II tissue samples across activin (+) and (-) AOIs in our cohort and the fact that circulating levels of activin do not differ between stages II and III29, activin may not be an optimal biomarker of disease or therapeutic target early in CRC.